Cold chain for cell & gene therapies

01Overview and value chain#

Markers EC: US FDA 21 CFR Part 210/211 + EU GMP Annex 1 for chain-of-identity and chain-of-custody in advanced therapy logistics | OECD: Bio-pharmaceuticals | Regulator: FDA (USA), EMA (EU), NMPA (China)

Cold chain for cell and gene therapies is the logistics service layer that moves a patient’s own cells (autologous) or a donor-derived product (allogeneic) between collection site, manufacturing facility and point of administration, distinct from the cryogenic tanks, freezers and shippers that provide the underlying equipment. For an autologous CAR-T therapy, the same physical unit that leaves a patient as a starting material must return to that same patient as a finished, temperature-critical product — a chain-of-identity requirement layered on top of the chain-of-custody every logistics network must maintain. A specialized courier manages the door-to-door itinerary, customs clearance for cross-border shipments, real-time temperature and location tracking, and contingency response if a flight is cancelled or a shipment is delayed, coordinating between the collection center, the manufacturing site (which may be on a different continent) and the treating hospital. This service layer sits downstream of the cryogenic hardware (EQP-066) and general biospecimen logistics (SVC-134) — it is specifically the advanced-therapy-focused courier and program-management capability, not the tanks and freezers themselves, and not general clinical-trial specimen transport.

The key directions of cold chain for cell and gene therapies are:

1. Chain-of-identity courier networks: door-to-door logistics providers that track and preserve the one-to-one link between a patient’s starting material and the finished therapy product returned to that same patient.
2. Advanced-therapy-specific program management: dedicated logistics coordination teams that manage the full itinerary across collection, manufacturing and administration sites, often spanning multiple countries and regulatory jurisdictions.
3. Real-time temperature and location tracking: connected monitoring across every leg of the shipment, with proactive alerting and contingency response for flight delays or customs holds that could jeopardize product viability.
4. Cross-border customs and regulatory clearance: specialized import/export handling for biological material, navigating country-specific requirements for temperature- sensitive, patient-specific therapeutic products.

Sectoral value chain#

[Patient/donor collection site] ──> [Chain-of-identity labeling & packaging]
                                                    │
                                          (temperature-controlled courier network)
                                                    │
                                                    ▼
[Patient administration site] <─── [Customs/regulatory clearance] <─── [Manufacturing facility]

Value chain levels#

Cross-cutting technologies of the sector:

• Chain-of-identity software platforms: dedicated tracking systems that link each physical shipment to a specific patient record across every handoff, distinct from general shipment tracking.
• Multi-modal temperature-controlled routing: logistics networks combine air, ground and cryogenic dry-vapor packaging to match each leg of the journey to the product’s stability window.
• Proactive contingency protocols: pre-established backup routing and courier redundancy for time- and temperature-critical shipments, reducing the risk that a single flight cancellation jeopardizes an irreplaceable patient-specific product.

02US#

The US hosts the category’s leading advanced-therapy logistics providers, serving the world’s largest concentration of cell and gene therapy manufacturing and clinical administration sites.

advanced-therapy logistics network depth, chain-of-identity program management leadership#

• World Courier: positions itself specifically around chimeric antigen receptor (CAR-T) and other cell/gene therapy logistics, with dedicated program messaging around the zero-margin-for-error nature of moving these products across long distances.
• Cavalier Logistics: provides turn-key cold chain and multi-temperature order handling for biopharma logistics, with dedicated messaging around cold-chain and pharma-logistics precision.
• Fisher Clinical Services: manages complex sample and investigational-product logistics specifically in support of cell and gene therapy programs, including packaging, labeling and cold-chain coordination for global clinical programs.

03CN#

No China-headquartered advanced-therapy logistics provider was screened in this round; demand is driven by China’s expanding cell and gene therapy clinical and commercial base, currently served largely through the same global logistics networks operating in the US and EU.

import- and global-network-served market, domestic cell/gene therapy clinical build-out#

• Global network coverage: World Courier, Marken and other global advanced-therapy logistics providers maintain China operations serving domestic cell and gene therapy clinical trials and commercial distribution.
• Domestic cell/gene therapy build-out: China’s growing cell and gene therapy clinical and manufacturing base is the main demand driver for advanced-therapy logistics capacity, without a confirmed domestic chain-of-identity courier network identified in this screen.
• Screening note: this screen focused on US/EU-headquartered global networks, given their established China operations; a dedicated China-originated candidate was not probed in this round.

04EU#

The United Kingdom hosts a global leader in advanced-therapy logistics specifically, with deep specialization in the cell and gene therapy chain-of-identity and program-management capability the category requires.

advanced-therapy logistics specialization, global program-management leadership#

• Marken (UK): provides dedicated advanced-therapy logistics with published learning-center content specifically on cell and gene therapy logistics operations, positioning the company around the precision required for this therapy class rather than general pharma cold chain.

05Leading companies and research institutes#

06Tech stack and innovations#

The stack layers chain-of-identity tracking, multi-modal temperature-controlled routing and cross-border regulatory clearance on a common contingency-management backbone.

1. Chain-of-identity tracking systems:
   • Dedicated software links each physical shipment to a specific patient record across every handoff, a requirement distinct from general shipment tracking because an autologous product must return to the exact same patient it originated from.
   • Tracking persists across collection, manufacturing and administration legs, often spanning multiple couriers, countries and regulatory jurisdictions.
2. Multi-modal temperature-controlled routing:
   • Logistics networks combine air, ground and cryogenic dry-vapor packaging to match each leg of the journey to the product’s stability window, switching modes as needed to preserve product integrity.
   • Route planning accounts for customs-hold risk and flight-schedule reliability specifically for temperature- and time-critical patient-specific shipments.
3. Proactive contingency protocols:
   • Pre-established backup routing and courier redundancy reduce the risk that a single flight cancellation or customs delay jeopardizes an irreplaceable patient-specific product.
   • Real-time alerting triggers a pre-planned response the moment a temperature or schedule deviation is detected, rather than after the shipment has already been compromised.

07Value chains and production pipelines#

Industrial pipeline of cell/gene therapy cold-chain logistics (21 CFR Part 210/211 / EU GMP Annex 1)#

┌───────────────────────────┐      ┌───────────────────────────┐
│ 1. Collection-site           │ ───> │ 2. Chain-of-identity          │
│    coordination              │      │    labeling & packaging       │
└───────────────────────────┘      └───────────────────────────┘
                                                 │
                                                 ▼
┌───────────────────────────┐      ┌───────────────────────────┐
│ 4. Customs/regulatory        │ <─── │ 3. Temperature-controlled     │
│    clearance                 │      │    transport                  │
└───────────────────────────┘      └───────────────────────────┘
              │
              ▼
┌───────────────────────────┐      ┌───────────────────────────┐
│ 5. Contingency management    │ ───> │ 6. Delivery & documentation  │
└───────────────────────────┘      └───────────────────────────┘

Stage 1: Collection-site coordination

The logistics provider coordinates pickup timing and initial packaging at the apheresis or biopsy collection site, initiating the chain-of-identity record.

Stage 2: Chain-of-identity labeling and packaging

The shipment is labeled with a unique identifier linking it to a specific patient and packaged to the temperature-stability requirement of the product.

Stage 3: Temperature-controlled transport

A specialized courier network manages door-to-door transport, using cryogenic or controlled-ambient packaging matched to the product’s stability profile.

Stage 4: Customs and regulatory clearance

Cross-border shipments undergo specialized import/export handling for temperature- sensitive, patient-specific biological material.

Stage 5: Contingency management

Real-time monitoring flags flight delays, customs holds or temperature excursions, triggering a pre-planned contingency response to protect product viability.

Stage 6: Delivery and documentation

The product reaches the manufacturing or administration site with a complete, auditable chain-of-custody and chain-of-identity record, meeting 21 CFR Part 210/211 and EU GMP Annex 1 documentation requirements.